期刊
JOURNAL OF HYPERTENSION
卷 28, 期 9, 页码 1796-1803出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/HJH.0b013e32833b912c
关键词
alpha-blockers; doxazosin; gastrointestinal therapeutic system; hypertension; metabolic effects
资金
- Pfizer Inc.
- Pfizer
- Novartis
- Servier
- Merck-Schering-Plough
- AstraZeneca
- Sanofi
- Boeringer
- Merck
- Roche Diagnostics
- Takeda and research
- National Institute for Health Research [NF-SI-0509-10222] Funding Source: researchfish
The role of alpha-1 adrenoceptor antagonists (alpha-blockers) in the management of hypertension continues to evolve. Recent data support their use as add-on therapy in uncontrolled hypertension when used in combination with all other major classes of antihypertensive drug and there is increasing evidence suggesting that they have modest but significant beneficial effects on lipid and glucose metabolism. The availability of extended-release formulations has contributed to an excellent tolerability profile. New data from an observational analysis of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) suggest that doxazosin gastrointestinal therapeutic system (GITS) used as a third-line antihypertensive agent lowered blood pressure and caused modest reductions in plasma lipids. Furthermore, use of doxazosin in ASCOT was not associated with an increased risk of heart failure, in contrast to the earlier finding of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Overall, currently available data support the use of alpha-blockers as safe, well tolerated and effective add-on antihypertensive drugs, which have additional favourable metabolic effects. J Hypertens 28:1796-1803 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据